Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $5,556,300.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMOGet Free Report) CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Thermo Fisher Scientific Trading Down 0.0 %

Shares of TMO stock opened at $550.82 on Friday. The stock has a 50 day simple moving average of $533.33 and a 200 day simple moving average of $514.38. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $593.17. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The stock has a market cap of $212.82 billion, a P/E ratio of 35.65, a price-to-earnings-growth ratio of 2.32 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.40 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Tuesday, November 14th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TMO shares. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $660.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, October 26th. Citigroup boosted their target price on Thermo Fisher Scientific from $530.00 to $575.00 and gave the stock a “buy” rating in a report on Monday, December 11th. Robert W. Baird reaffirmed an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price objective on the stock. Finally, Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $596.00.

View Our Latest Stock Report on TMO

Institutional Trading of Thermo Fisher Scientific

Large investors have recently made changes to their positions in the company. DMC Group LLC increased its stake in shares of Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after purchasing an additional 84 shares during the last quarter. Montchanin Asset Management LLC grew its position in Thermo Fisher Scientific by 1.1% in the second quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company’s stock valued at $2,374,000 after acquiring an additional 50 shares during the last quarter. Check Capital Management Inc. CA bought a new position in shares of Thermo Fisher Scientific in the third quarter worth about $219,000. Tower Bridge Advisors boosted its stake in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company’s stock valued at $16,727,000 after purchasing an additional 155 shares in the last quarter. Finally, Orion Portfolio Solutions LLC increased its position in Thermo Fisher Scientific by 7,323.0% during the 2nd quarter. Orion Portfolio Solutions LLC now owns 56,860 shares of the medical research company’s stock worth $29,667,000 after purchasing an additional 56,094 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.